Adalimumab has been studied in several clinical trials for the following conditions.
Ankylosing Spondylitis
Clinical studies have shown that adalimumab is effective at improving the symptoms of
ankylosing spondylitis, including
back pain and morning stiffness. People taking this medication showed greater improvements in their symptoms of ankylosing spondylitis, compared to those not taking it.
Crohn's Disease
Adalimumab was also studied for treating
Crohn's disease. In one study, up to 58 percent of those taking the drug showed significant improvement in their
Crohn's disease symptoms, compared to just 34 percent of those not taking it. Adalimumab also increased the chance of remission and helped keep the
symptoms of Crohn's disease from returning.
Juvenile Idiopathic Arthritis
In studies, children with juvenile idiopathic
arthritis who were given adalimumab with or without methotrexate (Rheumatrex
®) were less likely to have a disease flare-up, compared to children who were not given adalimumab.
Plaque Psoriasis
In one study, up to 71 percent of people who were treated with adalimumab for 16 weeks for
plaque psoriasis had "clear" or "minimal" disease, compared to just 10 percent of people who were not given it.
Psoriatic Arthritis
In a study of adalimumab for
psoriatic arthritis, adalimumab was shown to reduce pain and other
psoriatic arthritis symptoms, including joint stiffness. Also, the medication helped to lessen the physical joint changes of psoriatic arthritis, compared to those not taking it.
Rheumatoid Arthritis
In clinical studies looking at adalimumab as a
rheumatoid arthritis treatment, the medication was shown to improve the symptoms of
rheumatoid arthritis. More of the people taking adalimumab showed improvement, compared to the people not taking it. The medication also improved the physical joint changes that occur with rheumatoid arthritis.
Previous
